Efficacy News and Research

RSS

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company developing novel antioxidant molecules targeting mitochondria, today announced that it has achieved significant positive results in its U.S. Phase II clinical trial of SkQ1 compound in patients with moderate to severe dry eye syndrome.

24 Apr 2015

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

24 Apr 2015

Cardiff scientists make breakthrough asthma discovery

Cardiff University scientists have for the first time identified the potential root cause of asthma and an existing drug that offers a new treatment.

24 Apr 2015

Case Western Reserve and MIT receive $1.7 million to explore potential treatments for Down syndrome

Thanks to the generosity of a philanthropy dedicated to children's issues, renowned Down syndrome researcher Alberto Costa, MD, PhD, has taken yet another step toward making Northeast Ohio the nation's leader in exploring potential treatments of the genetic condition that affects 400,000 people in the U.S.

23 Apr 2015

Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Debiopharm International SA, part of Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) due to Staphylococci, including all resistant Staphylococcus strains, tested so far.

23 Apr 2015

Diabetes drug liraglutide could prove to be a new treatment option for NASH

A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at The International Liver Congress 2015. Results from a randomised controlled trial showed liraglutide met the primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis.

23 Apr 2015

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Data revealed today at The International Liver Congress 2015 show that the long-term use of entecavir (ETV) or tenofovir (TDF) results in excellent 5-year survival for Caucasian patients with chronic hepatitis B (CHB), with more than 95% of patients surviving at 5 years and a significant proportion of deaths coming from liver-unrelated causes.

23 Apr 2015

Transportable MP Airdrive device enhances donor liver viability for transplantation

A new device has demonstrated it has the potential to enhance the viability of donor livers for transplantation. Results revealed today at The International Liver Congress 2015 show that the transportable machine perfusion (MP) Airdrive is able to effectively maintain the quality of livers derived from donation after circulatory death (DCD).

23 Apr 2015

Study supports use of vitamin E as effective treatment for NASH

Results revealed today at The International Liver Congress 2015 show that vitamin E (d-alpha-tocopherol) is an effective treatment for non-alcoholic steatohepatitis (NASH). NASH occurs when the liver becomes inflamed due to the accumulation of fat. Over time, persistent inflammation can lead to the formation of fibrous scar tissue in the liver and around its blood vessels, which can eventually cause cirrhosis.

23 Apr 2015

New brain mapping model could improve success rate of transcranial magnetic stimulation

Brain researchers from the Perelman School of Medicine at the University of Pennsylvania have developed a new brain mapping model which could improve the success rate of transcranial magnetic stimulation (TMS) in treating conditions including depression, neuropathic pain, and stroke.

23 Apr 2015

Cardiff scientists identify potential root cause of asthma and highlight new treatment option

Cardiff University scientists have for the first time identified the potential root cause of asthma and an existing drug that offers a new treatment.

23 Apr 2015

Study reveals impact of delaying HCV treatment

Data revealed today at The International Liver Congress 2015 highlights the impact of delaying treatment for the hepatitis C virus (HCV). Researchers found that treatment delays have a serious detrimental effect on treatment efficacy, increasing the risk of morbidity and mortality among patients.

23 Apr 2015

New Tel Aviv University study may pave way for personalized bipolar disorder treatment

Rapidly swinging from extremes of joy and energy to sadness, fatigue, and confusion, bipolar disorder (BD) patients feel desperate and largely alone in the world. And according to the National Institutes of Health, between 25-50 percent of the roughly 3% of Americans living with BD attempt suicide at least once.

23 Apr 2015

Nuvo Research provides details of new WF10 Phase 2 clinical trial for treatment of allergic rhinitis

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced additional details of its new Phase 2 clinical trial (the 2015 WF10 Trial) to assess WF10 for the treatment of allergic rhinitis.

22 Apr 2015

Study finds increasing size of elderly population as major contributor to TB infection in China

A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to preliminary new research presented today at the Fourth Global Forum on TB Vaccines in Shanghai.

22 Apr 2015

New treatment shows promise in easing symptoms of Parkinson's disease

To date, a cure for Parkinson's disease remains elusive for the more than 50,000 Americans diagnosed yearly, despite decades of intensive study. But a newly approved treatment that might help ease the symptoms of Parkinson's has shown remarkable promise.

22 Apr 2015

New class of drugs targeting blood glucose level could benefit individuals with type 2 diabetes

Individuals with type 2 diabetes, who are resistant to insulin, have an excess blood glucose level, which they are now trying to reduce using a new class of diabetes drugs known as the gliflozins.

22 Apr 2015

Cantrixil drug granted FDA Orphan Drug Designation for treatment of ovarian cancer

US-Australian drug discovery company, Novogen, today announced that its subsidiary joint venture company with Yale University, CanTx, Inc, has today received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Cantrixil, has been granted Orphan Drug Designation for ovarian cancer.

22 Apr 2015

Cardio3 BioSciences reports absence of short term adverse events in first patient following NKG2D CAR T-cell infusion

Cardio3 BioSciences, soon to be renamed Celyad, a leader in engineered cell-therapy treatments today announced the infusion of the first patient enrolled in the Company’s Phase I clinical trial evaluating the safety and feasibility of its NKG2D CAR T-cell therapy, in cancer patients suffering from acute myeloid leukemia (AML) or multiple myeloma (MM).

22 Apr 2015

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS).

21 Apr 2015

Efficacy News and Research

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Cardiff scientists make breakthrough asthma discovery

Case Western Reserve and MIT receive $1.7 million to explore potential treatments for Down syndrome

Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Diabetes drug liraglutide could prove to be a new treatment option for NASH

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Transportable MP Airdrive device enhances donor liver viability for transplantation

Study supports use of vitamin E as effective treatment for NASH

New brain mapping model could improve success rate of transcranial magnetic stimulation

Cardiff scientists identify potential root cause of asthma and highlight new treatment option

Study reveals impact of delaying HCV treatment

New Tel Aviv University study may pave way for personalized bipolar disorder treatment

Nuvo Research provides details of new WF10 Phase 2 clinical trial for treatment of allergic rhinitis

Study finds increasing size of elderly population as major contributor to TB infection in China

New treatment shows promise in easing symptoms of Parkinson's disease

New class of drugs targeting blood glucose level could benefit individuals with type 2 diabetes

Cantrixil drug granted FDA Orphan Drug Designation for treatment of ovarian cancer

Cardio3 BioSciences reports absence of short term adverse events in first patient following NKG2D CAR T-cell infusion

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News